Your Health, We Care
Osimertinib is an efficient and safe EGFR-TKI inhibitor, providing a new treatment option for EGFR mutant non-small cell lung cancer patients.
Osimertinib has been approved in multiple countries and regions around the world, including the United States, European Union, Japan, and China, for the second-line treatment of advanced non-small cell lung cancer patients who have developed EGFR T790M resistance mutations after EGFR-TKI treatment.
Explore osimertinib and its role in the treatment of lung cancer, as well as its···【more】
Release date：2025-02-28Recommended：80
Explore the price of osimertinib and its role in treatment, as well as learn how···【more】
Release date：2025-02-28Recommended：83
